Searchable abstracts of presentations at key conferences in endocrinology

ea0022p589 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

The influence of the successful treatment of acromegaly on tissue distribution and overall BMD

Poteshkin Yuriy , Pronin Vyacheslav , Sokolina Irina , Gitel Evgeniy

Acromegaly (A) is associated with the bone overgrowth and soft tissue abnormalities due to anabolic, lipolytic and sodium retaining actions of GH.Aim: To investigate the effects of medical treatment on bone mineral density (BMD) of proximal femur, lumbar spine and tissue distribution. We observed 56 patients (14 M and 42 F) with A. BMD was measured using dual-energy X-ray absorptiometry with ‘total body’ program. The patients were treated with ...

ea0020p293 | Clinical case reports and clinical reports | ECE2009

Prevalence and peculiarity of arterial hypertension treatment in acromegaly patients

Melnichenko Galina , Syirkin Abram , Pronin Vyachelav , Svet Alexey , Chaplyigina Ekaterina , Gitel Evgeniy , Poteshkin Yuriy

Occurrence of arterial hypertension (AH) in acromegaly (A) is the significant risk factor for sudden death. The study group included 232 patients with A aged 47–67 year (mean age 54). The duration of active phase of A was 7–17 years (median 11), GH levels were 23–19.2 ng/ml (mean 6.5), IGF-1 were 223–568 ng/ml (mean 354). AH was found in 186 patients (80.2%): 1st degree – 27%, 2nd – 32%, 3rd – 41%. Of 24-hour arterial blood pressure monitorin...